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Medication is an essential pillar in the pre-
vention and therapy of illnesses. Detailed 
knowledge of medication at population 
level is indispensable for estimating mor-
bidity and the related health care needs for 
the population, and thus of great relevance 
for public health [1]. Information on the 
use of medicine is also interesting in terms 
of health economics. Roughly 17% of the 
expenditure of the statutory health insur-
ance funds went towards medication ther-
apies in 2010 [2]. It should be noted that 
in addition to the therapeutic effect, me-
dicinal products can also cause adverse ef-
fects which can impair or even endanger 
the health of users to a greater or lesser 
extent. In particular, the simultaneous use 
of several preparations can produce risks. 
Studies have demonstrated the correlation 
between the number of preparations used 
and the risk of drug interactions as well as 
adverse drug reactions [3, 4, 5, 6]. In addi-
tion to prescription drugs, over-the-coun-
ter (OTC) drugs acquired without a pre-
scription are also used. According to in-
formation provided by the pharmaceuti-
cal manufacturers’ association “Bundes-
verband der Arzneimittelhersteller e. V.”, 
people in Germany spent an average of 
roughly 60 € per person on OTC prepa-
rations in 2010 [7]. The use of self-medi-
cation and dietary supplements on top of 
prescribed medicinal products is proven 
to increase the risk of drug interactions [8, 
9, 10]. Drug interactions may not only im-
pair the health and quality of life of drug 
users, they also result in unnecessary costs 
within the health system and for the in-
dividuals. To estimate the use of medici-
nal products, it is of decisive importance 
to include the entire spectrum of drugs in 
the observation. The data provided by the 
health insurance funds can only reflect 
the segment of medication prescribed by 
a physician and reimbursed by the insur-
ance funds but information on prepara-
tions used for self-medication cannot be 
derived from this data.
A further restriction when assessing 
medication via prescription data is that 
actual consumption cannot be derived 
directly from the available data. Patient 
compliance with and adherence to the 
prescribed medication is decisive of what 
is actually consumed [11, 12, 13]. Against 
this background, the medication data col-
lected in the first wave of the German 
Health Interview and Examination Sur-
vey for Adults (DEGS1) proves to be suit-
able for filling information gaps on the use 
of drugs because it reflects all medicinal 
products (prescribed and self-medicated) 
as well as the extent and patterns of actu-
al usage behaviour. Because of the linkage 
of this data with health-relevant informa-
tion on living conditions and behaviour, 
it is also possible to provide a description 
of the determinants and profiles of med-
icine use.
The objective of this study is to de-
scribe the prevalence and spectrum of 
medication among the adult population 
in Germany. The focus of this study is the 
evaluation of the use of drugs and dietary 
supplements in association with sociode-
mographic and socioeconomic parame-
ters stratified by self-medication and pre-
scribed medication.
Materials and methods
The German Health Interview and Exam-
ination Survey for Adults (“Studie zur Ge-
sundheit Erwachsener in Deutschland”, 
DEGS) is part of the health monitoring 
system at the Robert Koch Institute (RKI). 
The concept and design of DEGS are de-
scribed in detail elsewhere [14, 16, 17, 18]. 
The first wave (DEGS1) was conduct-
ed from 2008–2011 and comprised inter-
views, examinations and tests [19, 20]. The 
target population comprises the residents 
of Germany aged 18–79 years. DEGS1 has 
a mixed design which permits both cross-
sectional and longitudinal analyses. For 
this purpose, a random sample from local 
population registries was drawn to com-
plete the participants of the German Na-
tional Health Interview and Examination 
Survey 1998 (GNHIES98), who re-partic-
ipated. There were 8,152 persons who par-
ticipated, including 4,193 first-time partic-
ipants (response rate 42%) and 3,959 re-
visiting participants of GNHIES98 (re-
sponse rate 62%). A total of 7,238 persons 
attended one of the 180 examination cen-
tres, and 914 were interviewed only. The 
net sample (n=7,988) permits representa-
tive cross-sectional and time trend analy-
ses for the age range of 18–79 years in com-
parison with GNHIES98 (n=7,124). The 
data of the revisiting participants can be 
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used for longitudinal analyses. The cross-
sectional and trend analyses are conduct-
ed with a weighting factor which corrects 
deviations in the sample from the popu-
lation structure (as of 31 Dec 2010) with 
regard to age, sex, region and nationali-
ty, as well as community type and educa-
tion [18]. A separate weighting factor was 
prepared for the examination part. Calcu-
lation of the weighting factor also consid-
ered re-participation probability of GN-
HIES98 participants, based on a logistic 
regression model. A non-response analy-
sis and a comparison of selected indicators 
with data from census statistics indicate a 
high level of representativity of the net 
sample for the residential population aged 
18–79 years of Germany [18]. To take into 
account the weighting as well as the cor-
relation of the participants within a com-
munity, the confidence intervals were de-
termined with the survey procedures for 
complex samples of SPSS-20 procedures 
for complex samples. Differences are re-
garded as statistically significant, if the re-
spective 95% confidence intervals do not 
overlap.
Social status was determined using 
an index which includes information on 
school education and vocational training, 
professional status and net household in-
come (weighted by household needs), al-
lowing for a classification into low, middle 
and high status groups [21].
Current medication intake is record-
ed via a computer-assisted personal inter-
view (CAPI) by an appropriately trained 
interviewer. In the letter of invitation, the 
survey participants are asked to bring 
with them all of the original packages of 
the medicines they have used in the last 
7 days prior to the examination date. With 
the question: “Have you taken any me-
dicinal products or dietary supplements 
within the last 7 days, such as vitamins or 
minerals? Please don’t forget any painkill-
ers, insulin preparations, medications is-
sued by a physician, injections or plant-
based medicinal products and please also 
list preparations from the supermarket or 
drugstore” it is ensured that not only the 
intake of drugs but also dietary supple-
ments are recorded, irrespective of wheth-
er they were prescribed or purchased over 
the counter.
A medication database (WIdO master 
data file) provided and constantly updated 
by the Research Institute of Local Health-
care Funds (WIdO) and a supplements 
database of the National Nutrition Survey 
(NVS) are integrated into the data record-
ing program (“Arzneimittel Erfassungs-
Datenbank”, AmEDa, Medication Record-
ing Database) [19]. The supplements da-
tabase enables the collection of informa-
tion on vitamin and mineral preparations 
which are not authorised medicinal prod-
ucts. The “Central Pharmaceutical Num-
ber” (PZN) is scanned at the study centre, 
thereby automatically recording the name 
of the preparation, the “Anatomical Ther-
apeutic Chemical” (ATC) code, the in-
dication group, the dosage form and the 
standard package size. If there is no PZN 
available, the brand name is documented. 
In addition to this, the indication and ori-
gin (prescribed vs. self-medicated) are re-
corded for every preparation (medicinal 
products and dietary supplements). All 
medications prescribed by a physician or 
alternative practitioner and all previous-
ly prescribed medicinal products kept at 
home in the medicine cabinet are pooled 
and categorized as prescription medica-
tion. Self-medication comprises prepara-
tions purchased independently without a 
prescription (“Over The Counter”, OTC) 
and non-prescription preparations kept at 
home in the medicine cabinet. Polyphar-
macy is defined as the use of five or more 
Tab. 1 Prevalence of medication use by sex, age and social status, DEGS1 2008–2011
Age Group n 18–29 years 30–39 years 40–49 years 50–59 years 60–69 years 70–79 years Total
Sex
Women 3,692 81.9% 78.1% 83.0% 83.9% 92.3% 96.3% 85.4%
(95% CI)  (77.6–85.6%) (72.8–82.5%) (79.4–86.0%) (80.9–86.6%) (88.5–94.9%) (93.8–97.8%) (83.9–86.9%)
Men 3,400 41.2% 52.7% 58.8% 67.0% 85.4% 94.9% 63.8%
(95% CI)  (36.2–46.4%) (46.4–58.9%) (53.7–63.7%) (62.3–71.4%) (82.0–88.2%) (92.0–96.8%) (61.6–66.1%)
Total 7,092 61.2% 65.2% 70.6% 75.5% 88.9% 95.7% 74.7%
(95% CI)  (57.4–64.9%) (60.9–69.2%) (67.3–73.7%) (72.6–78.1%) (86.4–91.0%) (94.0–96.9%) (73.3–76.0%)
Social status
Women
Low 611 79.4% 65.7% 75.7% 85.8% 89.1% 93.2% 83.0%
(95% CI)  (70.3–86.3%) (45.4–81.6%) (63.8–84.5%) (76.1–91.9%) (76.9–95.2%) (85.7–96.9%) (78.8–86.4%)
Medium 2283 84.1% 82.2% 85.1% 81.7% 93.3% 98.3% 86.9%
(95% CI)  (78.9–88.2%) (75.8–87.2%) (80.9–88.6%) (77.2–85.5%) (89.2–95.9%) (96.4–99.2%) (85.0–88.7%)
High 774 80.0% 73.5% 81.1% 88.8% 94.0% 93.1% 83.5%
(95% CI)  (68.1–88.3%) (62.6–82.1%) (73.0–87.2%) (81.2–93.6%) (87.2–97.3%) (83.2–97.4%) (79.4–86.9%)
Men
Low 545 41.5% 60.3% 60.9% 65.1% 85.5% 95.8% 65.4%
(95% CI)  (32.0–51.7%) (44.9–73.9%) (47.8–72.6%) (54.7–74.3%) (76.0–91.7%) (87.9–98.6%) (60.8–69.8%)
Medium 1919 40.9% 49.4% 57.2% 69.0% 84.9% 94.0% 62.7%
(95% CI)  (34.8–47.2%) (41.2–57.5%) (51.0–63.3%) (63.2–74.3%) (79.6–89.1%) (89.4–96.7%) (59.8–65.5%)
High 896 41.6% 56.1% 63.0% 62.2% 86.4% 98.4% 66.1%
(95% CI)  (29.7–54.6%) (44.5–66.9%) (54.5–70.7%) (51.7–71.7%) (80.1–91.0%) (95.7–99.4%) (61.6–70.4%)
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preparations (medicines and dietary sup-
plements), prescribed polypharmacy as 
the use of five or more prescribed prep-
arations. The duration of usage, dosage, 
frequency of use (regularly or as required) 
and use in the last 24 hours are also doc-
umented for every recorded preparation. 
If a preparation cannot be reliably identi-
fied at the study centre, an arrangement 
is made for the survey participant to be 
contacted by telephone or mail so that the 
missing information can be acquired [19].
Sociodemographic and socioeconom-
ic parameters from the questionnaires 
completed by the participants are includ-
ed to assess correlation to medication [21]. 
In addition to age, gender and social sta-
tus, medication is also stratified according 
to the size of the place of residence. Mu-
nicipality size is classified into the catego-
ries rural (<5,000 inhabitants), small town 
(5,000 to <20,000 inhabitants), medium-
sized town (20,000 to <100,000 inhabit-
ants) and city (>100,000 inhabitants).
A total of 7,092 persons (3,692 wom-
en and 3,400 men) participated in the 
medication interview. Most of the data 
were collected on the basis of the origi-
nal packages the participants brought in-
to the study centres. Only 1.5% of the men 
and women had to be subsequently con-
tacted per telephone or mail. By scanning 
the PZN, the relevant information includ-
ing ATC code was provided for 73% of the 
preparations, 27% had to be subsequent-
ly researched.
Results
Prevalence of medication use and 
number of preparations used
Of all adults aged 18–79 years, 74.7% 
(63.8% of men and 85.4% of women) had 
taken at least one preparation (medici-
nal product or dietary supplement) in the 
last 7 days. Prevalence rates among wom-
en are considerably and statistically sig-
nificantly higher than among men. An in-
crease in prevalence rates can be observed 
for both sexes with increasing age and it is 
more pronounced for men than for wom-
en. The greatest differences in the use of 
medicinal products are between men and 
women in the younger and middle age 
groups. These differences reduce with in-
creasing age until prevalence rates reach 
a virtually identical level for both sexes in 
the 70–79 age group. Differentiated by so-
cial status, no statistically significant gen-
der or age-specific differences can be ob-
served (. Tab. 1).
Women not only use medicinal prod-
ucts and dietary supplements more often 
than men, they also use more prepara-
tions on average (3.1 vs. 2.0 preparations). 
As for prevalence rates, an age progres-
sion can be observed for both sexes con-
cerning the average number of consumed 
preparations. The 18- to 29-year-old men 
indicated an average of 0.7 and women 
1.6 preparations. Up to the age group 70–
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Abstract
The first wave of the German Health Inter-
view and Examination Survey for Adults, 
2008–2011 (DEGS1), assesses current med-
icine use among participating adults aged 
18–79 years in the 7 days prior to the medi-
cal examination as part of a standardised in-
terview. About three quarters (74.4%) of 
all men and women state that they used at 
least one preparation. Prevalence is highest 
among 70–79 year olds (men 94.9%; wom-
en 96.3%). Overall women have a signifi-
cantly higher prevalence rate (85.4%) than 
men (63.8%). Preparations for the treatment 
of cardiovascular diseases are the most fre-
quently used medicines (men 27.2%; women 
29.5%). Polypharmacy (the use of 5 or more 
preparations) increases continuously with 
age and is observed significantly more often 
in women than in men in all age groups with 
the exception of the age group 70–79. Of the 
20,084 recorded preparations, 71.8% are pre-
scribed by a doctor and 27.7% are self-medi-
cated. While there are no differences in over-
all medication linked to social status, a so-
cial gradient is observed in prescribed prep-
arations and self-medication. The results pre-
sented here describe key indicators of med-
ication use representative of the German 
adult population. Based on the extensive da-
ta of DEGS1, further analyses into aspects 
such as co- and multimedication will be ad-
dressed in the future.
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Arzneimittelanwendung von Erwachsenen in Deutschland.  
Ergebnisse der Studie zur Gesundheit 
Erwachsener in Deutschland (DEGS1)
Zusammenfassung
In der ersten Erhebungswelle der Studie zur 
Gesundheit Erwachsener in Deutschland, 
2008–2011 (DEGS1), wird die aktuelle Arz-
neimittelanwendung in den letzten 7 Tagen 
vor der Untersuchung bei Erwachsenen (Al-
ter: 18 bis 79 Jahre) durch ein standardisiertes 
ärztliches Interview erfasst. Etwa drei Viertel 
(74,7%) aller Männer und Frauen geben an, in 
diesem Zeitraum mindestens 1 Präparat an-
gewendet zu haben. Bei den 70- bis 79-Jäh-
rigen ist die diesbezügliche Prävalenz am 
höchsten (Männer 94,9%; Frauen 96,3%). 
Bei Frauen findet sich mit 85,4% eine signifi-
kant höhere Prävalenzrate als bei Männern 
(63,8%). Am häufigsten werden Präparate 
zur Behandlung des Herz-Kreislauf-Systems 
(Männer 27,2%; Frauen 29,5%) eingesetzt. 
Polypharmazie (Einnahme von 5 und mehr 
Präparaten) steigt mit zunehmendem Al-
ter kontinuierlich an und wird – außer in der 
Gruppe der 70- bis 79-Jährigen – bei Frauen 
signifikant häufiger beobachtet als bei Män-
nern. Von 20.084 erfassten Präparaten sind 
71,8% vom Arzt verordnet, und 27,7% kom-
men über den Weg der Selbstmedika-
tion zum Einsatz. Während sich für die Arz-
neimittelanwendung insgesamt keine so-
zialschichtspezifischen Unterschiede zeigen, 
ist für die Selbst- und verschriebene Medika-
tion ein Sozialgradient zu erkennen. Die dar-
gestellten Ergebnisse beschreiben wesentli-
che Eckpunkte des Arzneimittelgebrauchs 
repräsentativ für die Erwachsenenpopulation 
in Deutschland. Basierend auf der umfang-
reichen Datenbasis werden zukünftig durch 
vertiefende Analysen weitere Aspekte wie 
Ko- und Multimedikation thematisiert.
Schlüsselwörter
Arzneimittelgebrauch · Männer · Frauen · 
Deutschland · Gesundheitssurvey
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79 years this increases among men to 4.7 
and among women to 5.5 preparations. 
The continuous increase in the average 
number of consumed preparations takes 
a particularly sharp increase in the 50–
59 age group. The level of consumed prep-
arations remains for women above that of 
men in all age groups (data not shown).
The prevalence of polypharmacy in-
creases in both sexes with advancing 
age. At the age of 70–79, almost half of 
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Fig. 1 9 Prevalence of 
polypharmacy by age and 
sex, DEGS1 2008–2011
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Fig. 2 9 Prevalence and 
ranking (first 10 places) of 
prescribed medication by 




all women (53.2%) state that they have 
used five or more preparations in the 
last 7 days. Women show a significant-
ly higher prevalence than men in this re-
gard in almost all age groups, with the 
exception of the 70–79 year olds. No dif-
ferences in polypharmacy prevalence are 
observed in this age group. The preva-
lence rate of prescribed polypharmacy is 
13.6% for women, which is significantly 
higher than the corresponding rate for 
men (9.9%). 
As with overall polypharmacy, the 
prevalence of prescribed polypharma-
cy also increases with age. This increase 
is particularly conspicuous for the age 
of 60+. Whereas the prevalence of over-
all polypharmacy in women of almost all 
age groups (exception 70–79 year olds), is 
significantly higher than in men, sex-spe-
cific differences for prescribed polyphar-
macy are only recorded for the 40–49 age 
group (. Fig. 1).
Medication spectrum
In addition to the prevalence and quan-
tity, the spectrum of preparations used 
permits conclusions on morbidity, sup-
ply and usage patterns of medication. The 
prevalences described by medication class 
(ATC class) and stratified for women and 
men are described in . Tab. 1.
Preparations for the treatment of the 
cardiovascular system (ATC code C) are 
the most commonly used by both men 
(27.2%) and women (29.5%). Most dom-
inantly within this ATC code are the use 
of antihypertensives (ATC code C02), di-
uretics (ATC code C03), beta blockers 
(ATC code C07), calcium channel block-
ers (ATC code C08), ACE inhibitors (ATC 
code C09) and cholesterol-lowering med-
icines (ATC code C10). Second place with 
28.3% of women and 16.6% of men is tak-
en up by the ATC class “V Various”, where 
dietary supplements (ATC code V06) are 
of greatest significance. Medications for 
the treatment of alimentary tract and me-
tabolism disorders (ATC code A) and ner-
vous system (ATC code N) follow in third 
and fourth place. Within the ATC code A 
it is antidiabetics (ATC code A10) and vi-
tamin and mineral preparations (ATC 
codes A11, A12) within the ATC code N it 
is analgesics (ATC code N02) and psycho-
tropic drugs (ATC code N05, N06) main-
ly determining the quantity of prevalence 
rates. With the exception of preparations 
for the treatment of the blood-forming or-
gans (ATC code B) and dermatologicals 
(ATC code D), women show considerably 
higher prevalence rates than men for all 
medication classes. As expected, the great-
est sex-specific differences are to be found 
in the use of hormone preparations (ATC 
classes G and H). The prevalence rates for 
women are almost four to six times high-
er than for men for both classes.
Prescribed medication 
versus self-medication
As the origin of virtually all preparations 
(prescribed vs. self-medication) is record-
ed separately in the medication interview 
it is possible to quantify both sources. Of 
20,084 recorded preparations, informa-
tion on the origin is available for 97.9%. 
The results of this study illustrate that 
medicinal therapy remains a domain of 
the physician. Accordingly, 71.8% of the 
preparations were prescribed by a doc-
tor, 27.7% were used by way of self-med-
ication and 0.4% originated from oth-
er sources. Within the study population, 
38.8% of the women and men have used 
medicines and dietary supplements with-
out a medical prescription and 58.8% with 
a medical prescription. Significant differ-
ences between men and women can be 
observed both in self-medication and pre-
scribed medication, whereas higher rates 
are recorded for women. The prevalence 
of self-medication and prescribed medica-
tion increases in both sexes with advanc-
ing age, whereby this increase is consider-
ably stronger for prescribed medication.
Tab. 2 Prevalence of medication use by ATC class and sex, DEGS1 2008–2011







A Alimentary tract system and metabolism 20.7% 17.2% 24.1%
(95% CI) (19.4–22.0%) (15.6–18.9%) (22.4–26.0%)
B Blood and blood-forming organs 11.2% 11.6% 10.8%
(95% CI) (10.3–12.1%) (10.5–12.8%) (9.6–12.2%)
C Cardiovascular system 28.4% 27.2% 29.5%
(95% CI) (27.1–29.7%) (25.4–29.1%) (27.8–31.3%)
D Dermatologicals 4.7% 4.8% 4.6%
(95% CI) (4.0–5.5%) (3.9–6.0%) (3.8–5.4%)
G Genito-urinary system and sex hormones 16.9% 4.8% 28.9%
(95% CI) (15.9–18.0%) (4.1–5.7%) (27.3–30.5%)
H Hormones, systemic excluding sex hormones 12.7% 5.4% 19.9%
(95% CI) (11.7–13.9%) (4.5–6.6%) (18.2–21.8%)
J Antiinfectives, systemic 1.7% 1.2% 2.1%
(95% CI) (1.3–2.1%) (0.8–1.8%) (1.6–2.8%)
L Antineoplastic and immunomodulating 
agents
1.5% 1.0% 1.9%
(95% CI) (1.2–1.8%) (0.7–1.5%) (1.5–2.4%)
M Musculo-skeletal system 17.1% 15.0% 19.1%
(95% CI) (15.9–18.3%) (13.5–16.7%) (17.5–20.9%)
N Nervous system 21.2% 16.6% 25.7%
(95% CI) (20.1–22.3%) (15.1–18.3%) (23.9–27.6%)
P Antiparasitic products, insecticides, repellents 0.1% 0.0% 0.2%
(95% CI) (0.1–0.3%) (0.0–0.1%) (0.1–0.5%)
R Respiratory system 12.1% 10.0% 14.3%
(95% CI) (11.2–13.2%) (8.7–11.3%) (12.8–16.0%)
S Sensory organs 4.2% 2.9% 5.5%
(95% CI) (3.6–5.0%) (2.3–3.7%) (4.4–6.9%)
V Various 22.5% 16.6% 28.3%
(95% CI) (21.3–23.8%) (15.1–18.2%) (26.6–30.1%)
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While no significant differences can 
be seen for overall medication regard-
ing social status, a social gradient can 
be recognised for self-medication and 
prescribed medication. With prescribed 
medication, higher usage rates are found 
among men and women with a lower or 
middle social status than among persons 
of high social status; the differences be-
tween middle and high social status are 
statistically significant. With self-med-
ication, prevalence rates increase with 
increasing social status. The differenc-
es in self-medication between low and 
high social status are statistically signifi-
cant. Self-medication is observed signif-
icantly more often in cities and medium-
sized towns than in rural areas. The op-
posite is the case for prescribed medica-
tion, where prevalence in the cities and 
medium-sized towns is significantly low-
er than in rural communities (<5,000 in-
habitants) (. Tab. 3).
Spectrum of prescribed 
medication and self-medication
The prevalence of prescribed medication 
is decisively influenced by the intake of 
ACE inhibitors (ATC code C09: 17.5%) 
and beta blockers (ATC code C07: 13.9%). 
This is followed by preparations for thy-
roid therapy (ATC code H03: 11.6%), sex-
ual hormones and modulators of the 
genital system (ATC code G03: 10.8%). 
Conspicuously, medicinal products for 
the treatment of cardiovascular diseas-
es are represented five times among the 
10 most commonly ingested medication 
groups (ACE inhibitors: ATC code C09, 
beta blockers ATC code: C07, lipid mod-
ifying agents ATC code: C10, antiplatelet 
drugs ATC code: B01, and calcium antag-
onists ATC code: C08). As expected, sig-
nificantly higher usage rates for thyroid 
therapy preparations (ATC code H03), 
sexual hormones and modulators of the 
genital system (ATC code G03) are to be 
found among women than men. Con-
trary to this, the prevalences of ACE in-
hibitors (ATC code C09), lipid modifying 
agents (ATC code C10) and antithrom-
botic agents (ATC code B01) are signifi-
cantly higher among men.
Tab. 3 Prevalence of self-medication and prescribed medication by sex, age, social status and municipality size, DEGS1 2008–2011
  Self-medication Prescribed medication
  Women Men Total Women Men Total
Total n=7092 46.4% 31.1% 38.8% 71.3% 46.1% 58.8%
(95% CI) (44.1–48.7%) (29.2–33.1%) (37.2–40.4%) (69.4–73.1%) (44.0–48.3%) (57.3–60.2%)
Age
18–29 years 39.4% 29.0% 34.1% 63.6% 16.4% 39.6%
(95% CI) (34.2–44.9%) (24.6–33.9%) (30.6–37.9%) (58.4–68.6%) (13.0–20.5%) (36.1–43.2%)
30–39 years 42.4% 33.5% 37.9% 61.7% 26.6% 43.8%
(95% CI) (36.7–48.2%) (28.2–39.3%) (33.8–42.1%) (56.1–67.0%) (21.7–32.0%) (39.9–47.8%)
40–49 years 50.9% 29.8% 40.1% 63.7% 38.7% 50.9%
(95% CI) (45.4–56.4%) (25.7–34.4%) (36.8–43.6%) (58.8–68.3%) (34.3–43.3%) (47.8–54.0%)
50–59 years 45.2% 29.6% 37.4% 70.2% 49.9% 60.1%
(95% CI) (41.1–49.3%) (25.4–34.2%) (34.4–40.5%) (66.0–74.2%) (45.0–54.9%) (57.0–63.1%)
60–69 years 49.2% 30.7% 40.2% 83.9% 79.8% 81.9%
(95% CI) (44.3–54.2%) (25.9–35.8%) (36.6–43.9%) (79.4–87.5%) (75.9–83.1%) (79.0–84.4%)
70–79 years 51.5% 37.0% 44.9% 91.0% 89.2% 90.2%
(95% CI) (45.9–57.0%) (31.9–42.4%) (41.2–48.7%) (87.7–93.4%) (85.5–92.0%) (87.9–92.0%)
Social status
Low 38.7% 26.3% 32.7% 70.0% 49.0% 59.7%
(95% CI) (33.3–44.3%) (22.0–31.2%) (28.9–36.7%) (65.3–74.3%) (43.6–54.3%) (56.1–63.3%)
Medium 47.1% 31.2% 39.4% 73.8% 45.5% 60.2%
(95% CI) (44.3–49.9%) (28.7–33.9%) (37.6–1.3%) (71.5–75.9%) (43.0–48.1%) (58.4–1.9%)
High 52.4% 35.4% 43.0% 65.4% 45.7% 54.6%
(95% CI) (48.1–56.7%) (31.9–39.2%) (40.1–6.0%) (60.6–69.9%) (41.0–50.2%) (51.2–57.9%)
Municipality size class
Rurala 41.1% 27.8% 34.2% 76.2% 50.0% 62.6%
(95% CI) (36.3–46.2%) 23.9–31.9%) (30.8–37.7%) (72.2–79.8%) (45.1–54.9%) (59.2–5.8%)
Small townb 44.2% 29.0% 36.6% 72.5% 48.5% 60.6%
(95% CI) (40.2–48.3%) (25.1–33.1%) (33.5–39.9%) (68.8–75.9%) (44.4–52.6%) (57.5–3.6%)
Medium-sized townc 48.5% 33.8% 41.3% 71.1% 43.5% 57.6%
(95% CI) (44.1–52.8%) (30.4–37.4%) (38.6–44.0%) (67.6–74.3%) (39.9–47.3%) (55.1–0.0%)
Cityd 48.5% 32.0% 40.4% 68.3% 44.8% 56.7%
(95% CI) (44.1–52.9%) (28.3–35.9%) (37.2–3.6%) 64.7–71.7%) (40.8–48.9%) (54.0–9.4%)
95% CI 95% confidence interval. a<5,000 inhabitants. b5,000 to <20,000 inhabitants. c20,000 to <100,000 inhabitants. d≥100,000 inhabitants..
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Main topic
In the field of self-medication, prepa-
rations of the ATC group V06 (17.6%) are 
used most frequently. Here, particularly 
dietary supplements determine the prev-
alence rate. More than one person in ten 
has utilized preparations of this group 
without a medical prescription. This is 
followed in second place by analgesics 
(ATC code N02) with 8.6%. Self-medi-
cation with antiphlogistics and antirheu-
matics (ATC code M01) was recorded for 
4.3% of the study population, and prep-
arations for the treatment of coughs and 
common colds (ATC code R05) are used 
by 3.1% without a medical prescription. 
Including all ATC groups mentioned 
above, prevalence rates among women 
are significantly higher than among men. 
The differences are particularly striking 
concerning dietary supplements (ATC 
code V06) (. Fig. 3).
Discussion
Almost three quarters of all men and 
women in Germany currently use me-
dicinal products and/or dietary sup-
plements to treat illnesses, relieve com-
plaints and symptoms or promote health. 
Prevalence rates are higher among wom-
en than men. In addition to this, prev-
alence rates and the number of prepa-
rations used both rise with advancing 
age. Once pension age has been reached, 
the gender-specific differences decrease 
steadily, virtually disappearing among 
70- to 79-year-old men and women. Poly-
pharmacy as well as prescribed polyphar-
macy become continuously more signif-
icant with increasing age. These results 
are confirmed to varying degrees by pub-
lished data. Data on medication are re-
ported for the USA in the regularly con-
ducted Slone Survey, named after Dennis 
Slone [22]. In a random sample of tele-
phone numbers, household members are 
asked about their current use of medi-
cines and dietary supplements within the 
last 7 days. Prevalence rates were then 
already higher in 1998/99 with 81% and 
2006 with 82% than in Germany (71.5% 
in GNHIES98; 74.7% in DEGS1); this al-
so applies to the prevalence of polyphar-
macy (29% in the Slone Survey; 18.3% in 
DEGS1, recalculated data not shown in 
the Results).
A prevalence niveau for medication 
comparable with our study is to be found 
in the data of a Swedish health survey 
conducted as a population-based cross-
sectional study between 2001 and 2005. 
Medicine use among 2,816 randomly se-
lected men and women aged 30–75 years 
amounted to 71% [23]. In a census con-
ducted by Morgan et al. [9] in Australia, 
in which medicine use in the last 24 hours 
by people aged 50 years and older was 
recorded in a postal survey, medication 
prevalence rates came up to 87.1%. This 
corresponds roughly with the results of 
DEGS1 (85.4%, recalculated data not 
shown in the “Results” section), as long 
as only the over 50s are taken into con-
sideration in the analysis. With 43.3%, 




V60 Homeopath. and. anthroposoph.
R01, Nasal preparations
A12 Mineral supplements 
R05, Cough and cold preparations
M01, Anti-inamm. and antirheum.
N02, Analgesics
V06, General nutrients, dietary supplements
Total Women Men
Fig. 3 9 Prevalence and 
ranking (first 10 places) 
of self-medication by ATC 
group and sex, DEGS1 
2008–2011
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the prevalence of polypharmacy is con-
siderably higher in the survey of Morgan 
et al. than it is in our study (31.8%, recal-
culated data not shown in the “Results” 
section). A similarly high polypharmacy 
rate as in DEGS1 is seen by Nobili et al. 
[24] after analysis of the prescription da-
ta of the Italian National Health Service 
(NHS) for persons older than 65 years. 
In this study polypharmacy was record-
ed for one year preceding the study and 
they found that almost half of men (45%) 
and women (46%) aged over 65 were us-
ing polypharmacy. In DEGS1, polyphar-
macy is found in 42% of the men (recal-
culated data not shown in the “Results” 
section) and 51% of women (recalculated 
data not shown in the “Results” section) 
of this age group. Data of the Rotterdam 
study, a population-based prospective 
cohort study covering 7,983 persons aged 
55 and over, show a polypharmacy preva-
lence (≥4 preparations) of 20.3% [6].
The correlation proven in our analy-
sis of age and gender on the one hand and 
medication on the other is to be found in 
publications based on survey data [25, 26, 
27] and in analyses based on secondary or 
health insurance fund data [28, 29].
According to the DEGS1 data, the ma-
jority of medicinal products are still tak-
en on the advice of a physician. Where 
prescription medication is concerned, 
drugs for the treatment of cardiovascu-
lar disorders dominate, which means that 
our data are comparable with published 
data of national and international studies 
[9, 30, 31, 32, 33]. However, according to 
DEGS1 results a considerable number of 
persons uses medicinal products—above 
all supplements—by way of self-medica-
tion. Dietary supplements and analgesics 
are the main preparations used for self-
medication. Compared to the results of 
the National Health and Nutrition Sur-
veys (NHANES I–III) [34], the preva-
lence rates for current use of dietary sup-
plements determined in DEGS1 are low-
er. However, as the intake of dietary sup-
plements in NHANES was recorded for 
one whole month, the time frame was 
here considerably longer than in DEGS1 
(7 days).
The increase in the self-medication 
rate with increasing social status was al-
ready asserted in the data of the 1998 Ger-
man National Health Interview and Ex-
amination Survey in which a representa-
tive random sample of the resident pop-
ulation of Germany aged 18–79 years was 
questioned about medication in the pre-
ceding 7 days. For both genders, simulta-
neous or exclusive self-medication is as-
sociated with a high social status [35]. A 
Spanish study representative of the pop-
ulation, in which the self-medication rate 
during acute illness is associated with a 
higher level of education, which often 
means a higher social status too, comes 
to similar results [1].
When comparing the results of these 
studies with those of DEGS1, however, it 
should be taken into account that medi-
cation use and polypharmacy, prescribed 
medication and self-medication were de-
fined differently in each instance and that 
there were differences in the observation 
and data collection periods which can 
lead to different estimators. Moreover, 
the comparability of the study results can 
be restricted by differences in the study 
populations regarding age, sex or setting.
Strengths and limitations
Because DEGS1 is a study representa-
tive of the population, it permits gen-
eralisations on medication usage of the 
adult population in Germany. In asso-
ciation with health-relevant informa-
tion from the survey, DEGS1 allows con-
clusions to be drawn regarding use pat-
terns and user profiles under everyday 
conditions and independent of the util-
isation of medical services. By recording 
data on overall medication, it is possible 
to assess self-medication which cannot 
be done with prescription data. It has a 
limiting effect because the collected da-
ta describe current medication use and 
are based on self-reporting. It was possi-
ble to validate this information as the re-
spondents brought the original packages 
of the preparations they had used to the 
study centre, where they were scanned. 
By scanning in the central pharmaceuti-
cal number (PZN), all information on the 
preparation, such as the name and ATC 
code, is transferred automatically to the 
database. Where information on prepa-
ration designations is missing, all avail-
able medication information systems are 
accessed or research is conducted in the 
internet. If a medication or dietary sup-
plement cannot be clearly identified, an 
ATC code is issued on an aggregated lev-
el. The percentage of misclassified prep-
arations (ATC code) is minimised in this 
way. Classification remains a problem, 
however, with unspecific designations 
which are sold as medicinal products (vi-
tamins and minerals, ATC code A11 and 
A12 respectively) or as dietary supple-
ments (ATC code V06). A misclassifica-
tion bias cannot be completely excluded 
here. This becomes clear when making a 
comparison with the results on the use of 
vitamins and minerals from GNHIES98, 
where the prevalence rates for the use of 
these preparations (ATC code A11or A12) 
given by Beitz et al. [35] are far higher 
than the prevalence estimates reported 
here in DEGS1. At the same time, the di-
etary supplements (ATC code V06) in 
GNHIES98 with prevalence rates far low-
er than those determined in DEGS1 are 
of negligible importance.
The restriction of the survey to drug 
use of the last 7 days has the effect on the 
one hand that errors due to poor mem-
ory (recall bias) are minimised. On the 
other hand, however, interruptions in the 
use of medicinal products that are used 
cyclically within this time frame can lead 
to a misclassification and thereby to a po-
tential underestimation of use in general 
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